Scholar Rock Gains FDA Approval for ISEMBYLD; Citigroup Raises Price Target

Key Facts

1Scholar Rock secured U.S. FDA approval for ISEMBYLD, a novel treatment for spinal muscular atrophy (SMA).

2Citigroup maintained its 'Buy' rating and raised its price target for SRRK to $74.00 from $60.00.

In a move reflecting a major clinical milestone for the biotech sector, Scholar Rock has secured U.S. FDA approval for ISEMBYLD, a novel treatment for spinal muscular atrophy (SMA). This approval marks the first muscle-targeted therapy for the condition, authorized for use in both children and adults already undergoing other treatments. According to reports, this regulatory success significantly improves the company's long-term valuation outlook following the successful navigation of clinical requirements.

Following the announcement, Citigroup maintained its 'Buy' rating on the stock and raised its price target to $74.00 from $60.00. This analyst action coincides with steady performance across major financial institutions; per market data, Citigroup (C) closed at $138.82 on September 11, 2026. In comparison, peer financial instruments such as JPMorgan Chase (JPM) and Wells Fargo (WFC) stood at $356.23 and $90.26 respectively as of the same closing date.

Scholar Rock (SRRK) was priced at $55.41 at the close of September 11, 2026, having reached a day high of $56.94. Investors are now watching for the stock's momentum toward the new analyst target following the formal approval catalyst. While the upcoming economic calendar shows no direct events for the company, broader market sentiment may be influenced by global interest rate decisions and inflation data scheduled for the coming week.